Market Research Logo

Secondary Hyperparathyroidism - Pipeline Review, H2 2015

Secondary Hyperparathyroidism - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Secondary Hyperparathyroidism - Pipeline Review, H2 2015’, provides an overview of the Secondary Hyperparathyroidism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Secondary Hyperparathyroidism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Secondary Hyperparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Secondary Hyperparathyroidism Overview
Therapeutics Development
Pipeline Products for Secondary Hyperparathyroidism - Overview
Pipeline Products for Secondary Hyperparathyroidism - Comparative Analysis
Secondary Hyperparathyroidism - Therapeutics under Development by Companies
Secondary Hyperparathyroidism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Secondary Hyperparathyroidism - Products under Development by Companies
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
Amgen Inc.
Deltanoid Pharmaceuticals Inc.
Mitsubishi Tanabe Pharma Corporation
Nektar Therapeutics
OPKO Health, Inc.
Secondary Hyperparathyroidism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Calcifediol MR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcimimetic-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTA-091 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTAP-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etelcalcetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lunacalcipol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-4580 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKTR-228 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-411 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Secondary Hyperparathyroidism - Recent Pipeline Updates
Secondary Hyperparathyroidism - Dormant Projects
Secondary Hyperparathyroidism - Dormant Projects
Secondary Hyperparathyroidism - Discontinued Products
Secondary Hyperparathyroidism - Product Development Milestones
Featured News & Press Releases
Jul 28, 2015: FDA Accepts OPKO's New Drug Application for Rayaldee
May 29, 2015: OPKO Announces Submission of Rayaldee New Drug Application to U.S. Food and Drug Administration
May 29, 2015: Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
Mar 27, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings
Mar 06, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference
Feb 25, 2015: Amgen Announces Positive Results from Head-To-Head Study Comparing the Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
Sep 23, 2014: OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints
Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Secondary Hyperparathyroidism, H2 2015
Number of Products under Development for Secondary Hyperparathyroidism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Secondary Hyperparathyroidism - Pipeline by Amgen Inc., H2 2015
Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Secondary Hyperparathyroidism - Pipeline by Nektar Therapeutics, H2 2015
Secondary Hyperparathyroidism - Pipeline by OPKO Health, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Secondary Hyperparathyroidism Therapeutics - Recent Pipeline Updates, H2 2015
Secondary Hyperparathyroidism - Dormant Projects, H2 2015
Secondary Hyperparathyroidism - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Secondary Hyperparathyroidism, H2 2015
Number of Products under Development for Secondary Hyperparathyroidism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report